Arimidex

Anastrozole, sold under the brand name Arimidex, is a third-generation nonsteroidal aromatase inhibitor. Chemically it is a triazole compound, related to other azole aromatase inhibitors such as letrozole. It works by shutting down the enzyme aromatase, which the body uses to make estrogen, and it is now widely available as a generic medicine.

The drug was patented in the late 1980s by the company that became AstraZeneca and was approved for medical use in 1995. It was among the aromatase inhibitors that reshaped hormone therapy for breast cancer, in many settings displacing the older drug tamoxifen for postmenopausal women.

Anastrozole is used chiefly for breast cancers that carry hormone (estrogen or progesterone) receptors. It serves as adjuvant treatment after surgery to reduce the chance of recurrence, as treatment for advanced or metastatic disease, and for prevention in postmenopausal women at high risk. Its evidence rests on large randomized trials. The ATAC trial compared anastrozole with tamoxifen as adjuvant therapy and found, at five years and again at ten years of follow-up, that anastrozole improved disease-free survival and reduced recurrence in hormone-receptor-positive patients ^[1][2]. The IBIS-II prevention trial showed that anastrozole roughly halved the incidence of breast cancer in high-risk postmenopausal women compared with placebo ^[3].

Because it works by lowering estrogen, anastrozole's side effects mirror an estrogen-deficient state: hot flashes, joint and muscle aches, vaginal dryness, and, importantly, accelerated bone loss that can raise the risk of osteoporosis and fractures. Compared with tamoxifen it tends to cause fewer blood clots and uterine problems but more bone and joint effects ^[1]. It is not used in pregnancy.

Anastrozole is a prescription medicine taken by mouth. It is highly effective at suppressing estrogen production, with studies showing near-complete inhibition of aromatase activity at standard doses ^[4]. Off-label, it has been used in other estrogen-related situations, including in some men and adolescents, though such uses are more limited and specialized.

Arimidex (anastrozole) is an aromatase inhibitor that lowers estrogen, and estrogen suppression commonly causes hot flashes, joint and muscle pain, and fatigue while reducing bone mineral density, which raises the risk of osteoporosis and fractures with prolonged use. It can also worsen the lipid profile and cause headache and mood changes, and excessive estrogen suppression carries its own harms. It is contraindicated in pregnancy.

Anastrozole inhibits cytochrome P450 3A4 (CYP3A4), potentially altering the clearance of drugs metabolized by this pathway. In clinical studies, concomitant use with substrates of CYP3A4 such as abemaciclib resulted in markedly increased systemic exposure; carriers of CYP3A4 loss-of-function alleles experience higher anastrozole concentrations than those with full enzyme activity, suggesting genotype-dependent effects. ^{[20] [21]} Herbal supplements containing CYP3A4 inhibitors have been shown to substantially increase anastrozole exposure; in rat studies, psoralen pretreatment raised the peak concentration from 56.74 ng/mL to 83.26 ng/mL and extended the half-life from 10.8 hours to 14.3 hours while decreasing systemic clearance. ^[22]

Checking a whole stack? Run it through interactions + stacks.

Anastrozole, marketed as Arimidex, was developed by the pharmaceutical company Zeneca, later part of AstraZeneca, as a potent nonsteroidal aromatase inhibitor. It received United States Food and Drug Administration approval in 1995, initially for advanced breast cancer in postmenopausal women whose disease had progressed on tamoxifen. The large ATAC trial, comparing anastrozole with tamoxifen as adjuvant therapy after surgery, supported its move to first-line use in early hormone-receptor-positive breast cancer. Its role in prevention was later established by the IBIS-II trial, whose long-term results, published in 2020, showed a durable reduction in breast cancer incidence among high-risk postmenopausal women.

Anastrozole is regarded as a cornerstone of endocrine therapy for postmenopausal, hormone-receptor-positive breast cancer, prized for its profound and reliable suppression of estrogen. Many oncologists favor it for both adjuvant treatment and, in selected high-risk women, prevention, where trial data show meaningful reductions in new cancers. Patients generally find once-daily dosing convenient, and the drug's benefits on recurrence are well documented. Its reputation is tempered honestly by the side effects that follow from deep estrogen deprivation, notably joint pain, hot flashes, and accelerated bone loss, which prompt many clinicians to monitor bone density and offer supportive measures.